MIMEDX, INC.
MARIETTA, GA

MiMedx Group, Inc. was incorporated on February 28, 2008. Its initial assets consisted of our HydroFix On January 5, 2011, the company acquired all of the outstanding equity interests in Surgical Biologics, LLC, and subsequently consolidated the corporate offices and operating facilities in Kennesaw, Georgia. This strategic acquisition brought together amnion tissue processing technology with MiMedx's experienced management team and extensive distribution network in order to position the company for market opportunities across multiple areas of medicine. After nearly two decades of human tissue experience, the Surgical Biologics founders had the vision to apply modern proprietary processing techniques to placental tissue to create unique ophthalmic, spinal, orthopedic, and dental implants. At the time of the acquisition, Surgical Biologics distributed tissue in several different membrane sub-segments, such as ocular, dental, and spine. Early 2011, MiMedx launched AmnioFix is used as a barrier membrane that reduces scar tissue formation between the dura and soft tissue. During 2011, the company launched EpiFix is an allograft specifically processed for acute and chronic wounds. The company further expanded its amnion product offering in 2011 with the introduction of AmnioFix MiMedx has built a management team with highly experienced healthcare executives with track records of leading large healthcare organizations in generating growth, producing profitability, and increasing shareholder value. Our management team draws on guidance from an insightful board of directors and medical advisory board. Collectively, they are committed to achieving success, accomplishing our corporate goals and growing the company. The management team at MiMedx Mr. Petit joined MiMedx Group in February 2009 as the Company’s Chairman and Chief Executive Officer. A visionary healthcare executive, Mr. Petit has a history of developing companies from their emerging stages and leading them to maturity and significant stature in their respective markets. In 1970, Mr. Petit founded Healthdyne, an international healthcare company that manufactured high technology healthcare devices, provided healthcare information systems and technology, and provided healthcare services and disease management. The Healthdyne related companies grew to annual revenues in excess of $1 billion. In order to increase shareholder values, Healthdyne was split into several publicly traded companies through public offerings and spinouts to shareholders. Subsequently, the home infusion therapy subsidiary was sold to W. R. Grace Corporation. In 1995, Healthdyne Maternity Management was merged with Tokos Medical to form Matria Healthcare. At that point, Mr. Petit relinquished the CEO role and remained Chairman of the Board of all the companies. In 1997, Healthdyne Technologies was merged with Respironics. Mr. Petit resumed the duties of President and CEO of Matria Healthcare in 2000. In 2001, Healthcare.com, which was formerly Healthdyne Information Enterprises, merged with XCare.net Corporation to form Quovadx. Through Mr. Petit’s vision and leadership, Matria Healthcare transitioned into the industry’s only fully integrated health, productivity and disease management care continuum providing employer and health plan clients access to wellness programs, nurse triage services, decision support programs, disease management programs for chronic diseases, case management programs for acute and catastrophic conditions and unparalleled health data integration and informatics. Matria Healthcare was sold to Inverness Medical Innovations in May of 2008 in a transaction valued at over $1.2 billion. Mr. Petit funded a professorial chair for “Engineering in Medicine” at Georgia Tech in 1986. In 1995, he endowed the Petit Institute for Bioengineering and Biosciences at Georgia Tech. In 2001, he helped fund the biotechnology building at Georgia Tech which has his name, and in 2004, the Science Center building at Georgia State University which also has his name. In 2007, he was inducted into the Georgia State Business School Hall of Fame. In October of 2011, Mr. Petit was inducted into the National Academy of Engineering. Mr. Petit received his bachelor’s degree in Mechanical Engineering and Master of Science degree in Engineering Mechanics from Georgia Tech. He received his MBA degree in Finance from Georgia State University in 1973. Mr. Taylor joined MiMedx Group in June 2009 as a consultant and in September 2009, he was named President and Chief Operating Officer He was appointed to the MiMedx Board of Directors in October 2011. Mr. Taylor is an operating executive with over 25 years’ experience leading fast growth medical device, design and manufacturing companies. Prior to joining MiMedx, Mr. Taylor was the Chief Executive Officer of Facet Technologies, LLC, the world-wide leader in microsampling devices, which were predominately used in diabetes care. Prior to being acquired by a private equity company, Facet was a wholly-owned subsidiary of Matria Healthcare, Inc. From 1994 through 1998, through the leadership of Mr. Taylor and the rest of the team, Facet grew from $14 million to nearly $40 million in revenue. Matria acquired Facet in 1999, and under Mr. Taylor’s leadership, Facet grew to be the global leader in microsampling devices with over a 50% market share and in excess of $85 million in revenue. During his 14 year career at Facet, he held various management positions, beginning with the Company’s head of R&D, QA & Regulatory Affairs and progressing through general management and ultimately, Chief Executive Officer. With Mr. Taylor as President and COO, MiMedx has put together an infrastructure that is more than capable of generating and serving the prolific demand for its products. Through Mr. Taylor’s operating expertise and the Company’s acquisition of exceptional talent, Mr. Taylor has positioned MiMedx in the critical areas of medical affairs, scientific research, product development, sales & marketing, regulatory affairs, engineering and operations to flawlessly perform through a rapid pace of year-over-year new product development and exponential sales growth.